• Promising results of rituximab in systemic sclerosis

    The largest routine care study of rituximab use in systemic sclerosis (SSc) patients showed significant changes in skin fibrosis but not in lung fibrosis.

  • Mechanism found: Why neurodevelopmental disorders affect more males than females

    The study of mice, published in Nature Communications, led to the discovery that the O-linked N-acetylglucosamine transferase (OGT) molecule sets sex-specific patterns of gene expression.

  • Long-term exposure show that apremilast significantly improves PsA

    Apremilast has demonstrated sustained and clinically meaningful improvements in signs and symptoms of psoriatic arthritis, as well as in physical function in patients who continued treatment over 5 years.

  • Up to 42% of cancer cases could be preventable through lifestyle choices

    A large, ongoing USA study with over 1.5 million cases analyzed lifestyle factors on tumorous cancer risk. The findings hint at how many cancer cases could be prevented with simple lifestyle changes.

  • HIPEC without effect in colorectal peritoneal carcinomatosis

    Hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis surgery does not improve survival and may increase the rate of complications compared to surgery alone.

  • Thousands of genes affected by DNA loop changes caused by the cancer-causing HTLV-1 virus

    New research exposes that the human leukemia virus (HTLV-1) disrupts the regulation processes of thousands of genes and changes intracellular DNA loops, raising the risk of a rare type of leukemia.

  • Rivaroxaban and ASA: The new dream team of CHD prevention?

    A combination therapy with aspirin and low-dose rivaroxaban appears to be more effective in the secondary prevention of cardiovascular events than aspirin monotherapy.

  • Pancreatic carcinoma: adjuvant mFolfirinox prolongs survival by nearly 20 months compared to gemcitabine

    With a modified folfirinox regimen, patients with non-metastatic pancreatic ductal carcinoma in adjuvant chemotherapy achieved a survival of 54.5 months compared to the previous gemcitabine standard of 35 months.

  • Baricitinib: a potential therapy for SLE patients

    Recent data has shown that once-daily oral 4 mg of baricitinib for patients with systemic lupus erythematosus (SLE) who receive standard background therapy, is associated with significant clinical improvements compared to placebo.

  • Advanced NSCLC: First line pembrolizumab, better than chemotherapy

    Immunotherapy with the PD1 inhibitor pembrolizumab acts as first-line therapy in patients with advanced NSCLC and PD-L1 expression ≥ 1% better than standard chemotherapy. Patients lived 4 to 8 months longer in the median, with fewer side effects.

  • Is a complete remission in many type 2 diabetes cases a possibility?

    The results of a Scottish cluster-randomized study on Type-2 diabetes indicate that the illness could be reversed without anti-diabetic medicines.

  • Switching to biosimilar bDMARDs, safe and effective?

    Biosimilars use has taken off in the past few years and is expected to increase further. Recent findings add to the increasing evidence that switching from originator to bDMARDs is safe and efficacious.

  • Revolutionary non-addictive painkiller might be the solution to the growing opioid epidemic

    Blue-181 molecule acts on spinal cord pain receptors instead of the brain, and arguably produces no narcotic or addiction side effects

  • Nephrectomy partially dispensable in advanced renal carcinoma

    Treatment with sunitinib alone was not inferior to nephrectomy followed by sunitinib in patients with advanced renal cell carcinoma and intermediate to high risk in effect on overall survival.

  • Synergistic effect NSAIDs + TNFi in slowing AS patients’ radiographic progression

    Dose-related NSAIDs with TNFi use in ankylosing spondylitis patients have a synergistic effect in slowing radiographic progression. The greatest effect is seen in those using both high-dose NSAIDs and TNFi.

  • Hospital cybersecurity: CT-scanners may be vulnerable to attacks

    In May 2018, Philips’ ICS-CERT unit released tips on the safety issues that could breach its Brilliance CT scanner. How severe and which other safety gaps are there in medical imaging systems?

  • New blood pressure guidelines in the USA

    At the last cardiology congress of the American Heart Association (AHA), new high blood pressure guidelines were presented. Values of 120/80 mmHg and above have been deemed high in the USA.

  • High-risk rhabdomyosarcoma: maintenance chemotherapy can improve survival rates

    Vinorelbine and low-dose cyclophosphamide therapies significantly increase overall 5-year survival in high-risk children with RMS, from 73.3% without maintenance therapy to 86.5%

  • A closer look at the role of bDMARDs in psoriatic arthritis

    Infliximab, etanercept, adalimumab, ixekizumab, ustekinumab, secukinumab, and certolizumab pegol provided improvements in health assessment questionnaire-disability index scores from baseline.

  • The role of microsatellite instability as a marker for Lynch syndrome

    Tumors with high microsatellite instability (MSI) are often associated with Lynch syndrome. Tumor patients with high MSI, and mutations in DNA mismatch repair genes should be checked for the syndrome.

  • 79 |
  • 80 |
  • 81 |
  • 82 |
  • 83 |
  • 84 |
  • 85 |
  • 86 |
  • 87 |
  • 88 |
  • 89 |